Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers

Area of Science:

• Cardiology
• Biomarker Research
• Medical Technology

Background:

• Heart failure (HF) prevalence remains high after acute myocardial infarction (AMI) despite advancements like primary percutaneous coronary intervention (PCI).
• Late adverse cardiac remodeling post-PCI is a significant risk factor for mortality and delayed HF manifestation.
• Limited research exists on biomarker utility specifically in AMI patients undergoing primary PCI.

Purpose of the Study:

• To review the role of circulating biomarkers in stratifying AMI patients.
• To identify patients at high risk for poor cardiac recovery and HF development after successful PCI.
• To highlight biomarkers indicative of inflammation, myocardial stress, injury, fibrosis, and endothelial dysfunction.

Main Methods:

• Literature review focusing on circulating biomarkers in AMI and HF.
• Analysis of biomarkers related to inflammation, biomechanical stress, cardiac injury, necrosis, fibrosis, endothelial dysfunction, and vascular repair.
• Discussion of clinical utilities and predictive capabilities of specific biomarkers (e.g., natriuretic peptides, troponins, galectin 3).

Main Results:

• Various circulating biomarkers show potential for risk stratification in AMI patients post-PCI.
• Biomarkers reflecting inflammation, myocardial stress, and fibrosis are crucial indicators of adverse cardiac remodeling.
• Specific biomarkers like natriuretic peptides, cardiac troponins, and galectin-3 have demonstrated predictive value.

Conclusions:

• Circulating biomarkers are a promising tool for identifying AMI patients at high risk of poor cardiac recovery and HF after PCI.
• Utilizing these biomarkers can lead to better risk stratification and personalized treatment strategies.
• Further research into the predictive power of various biomarkers is warranted for improved patient management.